Yahoo · Sep 16, 2026
Is Zimmer Biomet Stock Underperforming the Nasdaq?
As Zimmer Biomet has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain cautious about the stock’s prospects.
NYSE · ZBH
Zimmer Biomet Holdings, Inc.
Healthcare · Medical - Devices
$95.36
Up+$1.11 (+1.18%)
Updated Sep 20, 2026, 6:01 PM
SID Score
6.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 18.32B
- P/E ratio
- 22.74
- Dividend yield
- 1.01%
- 52-week range
- $79.12 – $102.86
- Volume
- 3.95M
- Avg. volume
- 1.84M
Price performance
ZBH price history
1M range · 19 trading sessions · Daily adjusted prices
ZBH closed at $95.36 after 19 trading sessions, down 5.57% for the selected period.
- Last close
- $95.36
- Period change
- -5.57%
- Period low
- $92.44
- Period high
- $101.38
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $94.04 | $96.165 | $93.715 | $95.36 | 3.95M |
| Sep 17, 2026 | $96.70 | $97.19 | $94.20 | $94.25 | 2.2M |
| Sep 16, 2026 | $97.75 | $98.41 | $96.39 | $96.78 | 1.89M |
| Sep 15, 2026 | $96.44 | $99.1825 | $95.87 | $98.41 | 3.62M |
| Sep 14, 2026 | $95.25 | $96.98 | $94.685 | $96.54 | 2.03M |
| Sep 11, 2026 | $92.95 | $93.64 | $91.74 | $93.49 | 1.88M |
| Sep 10, 2026 | $94.04 | $94.045 | $91.45 | $92.44 | 1.37M |
| Sep 9, 2026 | $93.02 | $95.73 | $92.55 | $94.61 | 2.07M |
| Sep 8, 2026 | $97.05 | $97.23 | $91.87 | $94.22 | 3.13M |
| Sep 4, 2026 | $97.77 | $98.765 | $96.8444 | $98.07 | 1.33M |
| Sep 3, 2026 | $100.06 | $101.81 | $98.15 | $98.92 | 1.28M |
| Sep 2, 2026 | $99.32 | $101.71 | $99.0079 | $99.50 | 1.39M |
| Sep 1, 2026 | $101.49 | $102.86 | $99.041 | $99.40 | 1.39M |
| Aug 31, 2026 | $100.20 | $100.30 | $99.53 | $100.04 | 1.3M |
| Aug 28, 2026 | $99.61 | $101.32 | $99.245 | $100.91 | 1.19M |
| Aug 27, 2026 | $99.93 | $101.28 | $99.21 | $99.48 | 1.35M |
| Aug 26, 2026 | $99.52 | $101.98 | $99.20 | $101.38 | 1.35M |
| Aug 25, 2026 | $100.14 | $100.87 | $99.28 | $100.24 | 1.27M |
| Aug 24, 2026 | $101.32 | $102.12 | $100.69 | $100.98 | 1.5M |
Latest ZBH news
The latest Smart Investors Daily articles mentioning ZBH.
Stock researchCompany · Overview
ZBH research
Overview
Company profile and research snapshot.
Company profile
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $112.29
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | Canaccord Genuity | Hold | — |
| Aug 7, 2026 | Truist Securities | Hold | — |
| Aug 6, 2026 | Bernstein | Market Perform | — |
| Aug 6, 2026 | Stifel | Buy | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 14, 2026
How Zimmer Biomet’s New Americas and Robotics Leadership Structure At Zimmer Biomet Holdings (ZBH) Has Changed Its Investment Story
Zimmer Biomet Holdings, Inc. recently announced a major reshuffling of its leadership structure, effective October 1, 2026, promoting Gary Campbell to President, Americas; Brian Hatcher to President, Recon, S.E.T., CMFT, Neuro and Biosurgery; and Bradley Kessler to President, Americas – Robotics, Technology and Data, while Group President Kevin Thornal exited on September 30, 2026. This overhaul elevates long-tenured internal leaders with deep orthopedic, robotics and commercial experience,...
SeekingAlpha · Sep 14, 2026
Stryker: Operational Issues Have Created An Opportunity
Stryker's share price declined significantly due to operational issues, valuation concerns, and weaker orthopedic procedure volume growth. Learn more about SYK stock here.
Yahoo · Sep 10, 2026
Zimmer restructures Americas leadership team
The company promoted three executives and eliminated a fourth position as part of changes intended to support its ongoing commercial transformation.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
